Levosulpiride y domperidona en el tratamiento de la dispepsia funcional: estudio comparativo


ABSTRACT _____________________________________________________________________________________________________________________ RESUMEN: Objetivo: Comparar la eficiencia en la reducción de los síntomas de pacientes diagnosticados mediante los criterios de Roma III con el diagnóstico de dispepsia funcional, a las 4 semanas de estar tomando levosulpiride o domperidona. Método: Se incluyeron 105 pacientes que consultaron con los síntomas de dispepsia funcional, al Servicio de Gastroenterología del Hospital Universitario de Caracas, que cumplían con los criterios de ROMA III, en un estudio prospectivo aleatorio. A todos se les realizó gastroscopia y biopsia para diagnosticar Helicobacter pylori. Tiempo de duración del estudio por cada paciente 30 días. Tiempo total del estudio 6 meses de noviembre de 2006 a abril de 2007. Resultados: El 94,28 % de los pacientes que recibieron levosulpiride reportaron síntomas leves o ausentes en comparación con el 71,42 % del grupo que recibió dinoprostona y el 14,28 % del grupo control. Conclusión: Levosulpiride es más eficaz que domperidona en el control de los síntomas de dispepsia funcional en los pacientes estudiados. Las drogas comparadas no presentaron efectos adversos severos. Levosulpiride, debería considerarse entre los fármacos de elección en el tratamiento de la dispepsia funcional. ABSTRACT: Objective: Compare efficiency in the reduction of symptoms of patients diagnosed according Rome III classification of functional dyspepsia, for 4 weeks of are taking Levosulpiride or Domperidona. Methods: Were included 105 patients that consulted with the symptoms of Functional Dyspepsia, to the Service of Gastroenterology of the University Hospital of Caracas, in a study prospective randomized. To all they are carried out Gastroscopy and biopsy to diagnose Helicobacter Pylori. Time of duration of the study for each patient 30 days. Total time of the study 6 months of November of 2006 to April of 2007. Results: 94.28 % of patients that received Levosulpiride was asyntomatic, comparing with 71.42 % Domperidona group and 14.28 % Control group. Conclusion: Levosulpiride is more effective than Domperidona in the control of the symptoms of functional dyspepsia in the studied patients. The compared drugs didn't present severe adverse effects. Levosulpiride, it should be considered among the drugs of choice for the treatment of the functional dyspepsia.

1 Follower
  • Source
    Gastroenterology 05/2006; 130(5):1377-90. DOI:10.1053/j.gastro.2006.03.008 · 13.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Impaired accommodation of the proximal stomach to a meal has been reported in functional dyspepsia, but its relevance to symptoms is unclear. The aim of this study was to test the hypothesis that impaired gastric accommodation causes early satiety. A gastric barostat was used to study postprandial fundus relaxation in 35 healthy subjects and 40 patients with functional dyspepsia. Gastric emptying, Helicobacter pylori status, sensitivity to gastric distention, and a dyspepsia symptom score were obtained from all patients. In addition, the effect of sumatriptan, a fundus-relaxing 5-hydroxytryptamine1 agonist, on gastric accommodation and on early satiety in dyspeptic patients was studied. Impaired gastric accommodation to a meal was found in 40% of the patients. In univariate analysis, this was associated with early satiety and weight loss but not with hypersensitivity to gastric distention, presence of H. pylori, or delayed gastric emptying. In a multivariate analysis, only early satiety was associated with impaired gastric accommodation. Sumatriptan restored gastric accommodation, thereby significantly improving meal-induced satiety. Impaired relaxation of the proximal stomach to a meal is present in a high proportion of patients with functional dyspepsia. It is associated with symptoms of early satiety. Restoring gastric accommodation with a fundus-relaxing drug improves early satiety.
    Gastroenterology 01/1999; 115(6):1346-52. DOI:10.1016/S0016-5085(98)70012-5 · 13.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sensorimotor disorders of the stomach, small intestine and colon have a limited repertoire of clinical manifestations, and there is the potential for more than one mechanism to lead to symptoms. In many recent clinical trial programs of novel agents in neurogastroenterology, the emphasis has been primarily on symptom assessment of broad groups of patients identified by the Rome criteria. Drugs of potential value have fallen by the wayside with this approach. We propose the current paradigm is partly to blame; physiological testing should provide the basis for identifying more homogeneous populations and therapeutic targets within functional bowel disease, and this applies to the upper and lower gut. Here we summarize the evidence that certain biomarkers can, in a limited fashion, be used to predict the success of an experimental medicine in common disorders of gastrointestinal function, including the irritable bowel syndrome and functional dyspepsia. Although the current evidence is limited and is most convincingly demonstrated with examples of transit measurements (for loperamide, alosetron, tegaserod and piboserod), we perceive this paradigm that studies using validated and responsive biomarkers have an important role to play in drug development.
    Neurogastroenterology and Motility 05/2004; 16(2):135-42. DOI:10.1111/j.1365-2982.2004.00516.x · 3.42 Impact Factor
Show more


Available from